Get to know our clinical trials
Clinical trial of BDC-1001 in monotherapy and in combination with nivolumab in patients with HER2-expressing advanced solid tumors
THE GOAL OF THIS STUDY IS TO SEE IF BDC-1001 (TAKEN ALONE OR TOGETHER WITH NIVOLUMAB) CAN HELP PEOPLE WITH THEIR TYPE OF CANCER AND TO SEE HOW THEY RESPOND TO THIS TREATMENT. ALL PATIENTS WHO CHOOSE TO PARTICIPATE IN THE STUDY WILL RECEIVE BDC-1001 ALONE OR BDC-1001 IN COMBINATION WITH NIVOLUMAB. BDC-1001 IS AN INTRAVENOUS (IV) DRUG, WHICH MEANS IT IS GIVEN DIRECTLY INTO A VEIN USING A NEEDLE OR TUBE.
Technical Summary
- PHASE I/II STUDY OF BDC-1001 IN MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED HER2-EXPRESSING SOLID TUMORS. IMMUNOTHERAPY
- Code EudraCT: 2021-006812-10
- Protocol number: BBI-20201001
- Promoter: Bolt Biotherapeutics
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs